FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

								vvasim	igion, D.	0.20	010					OMB	APPRO\	/AL	
Secti oblig	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940												OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
trans contr the p secu to sa cond	ck this box to indi action was made act, instruction o urchase or sale o rities of the issue tisfy the affirmativi itions of Rule 10t uction 10.	pursuant to a written plan for of equity r that is intended ve defense						()											
1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol								elationship		g Perso	on(s) to Issu	ier	
Incerti Carlo					Dyne Therapeutics, Inc. [DYN]								eck all applic	,	le) 10% Owner				
(Last)					3. Date of Earliest Transaction (Month/Day/Year) 11/18/2024										(give title	Other (s below)	pecify		
		PEUTICS, INC																	
1560 TRAPELO ROAD					4. lf	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WALTI											 Form filed by One Reporting Person Form filed by More than One Reporting Person 				I				
(City)	(S	tate)	(Zip)																
		Tab	ole I - No	n-Deriv	ative	e Seo	curit	ies Ac	quired	, Dis	sposed o	of, or Bei	reficial	y Owned					
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execution Date			Transaction Disposed Of Code (Instr.			Of (D) (Instr. 3, 4 and 5)) Securitie	5. Amount of Securities Beneficially Owned Following		Direct c	7. Nature of Indirect Beneficial Ownership		
				(Month/D	ayilea		Ionth/	Day/Year)	8)	Instr.				Owned I	Following	(D) or (I) (Ins	str. 4) 🛛 🛛 🔾	Beneficial Dwnership	
				(Month/D	ay/rea	(M	Ionth/	Day/Year)	8) Code	lnstr. V	Amount	(A) or (D)	Price	Benefici Owned I Reporte Transac (Instr. 3	Following d tion(s)	(D) or (I) (Ins	str. 4) 🛛 🛛 🕻	Beneficial	
Commo	n Stock			(Month/D	-	(N	lonth/	Day/Year)	8)		Amount 16,500	(D)	Price \$8.69	Owned I Reporte Transac (Instr. 3	Following d tion(s)	(I) (Ins	str. 4) 🛛 🛛 🕻	Beneficial Dwnership	
Commo					/2024	(M	lonth/	Day/Year)	8) Code		<u> </u>	(D) A	<u> </u>	Owned I Reporte Transac (Instr. 3	Following d tion(s) and 4)	(I) (Ins	str. 4) (Beneficial Dwnership	
			Table II -	11/18/ 11/18/ • Deriva	/2024 /2024 tive \$	Secu	lonth/l	es Acqu	8) Code M S uired, I	v Disp	16,500	(D) A D or Bene	\$8.69 \$28.73	Owned I Reporte Transac (Instr. 3 16	Following d tion(s) and 4) ,500	(I) (Ins	D	Beneficial Dwnership	
	on Stock	3. Transaction Date (Month/Day/Year)	Table II - 3A. Deem Execution if any (Month/Da	11/18/ 11/18/ • Deriva (e.g., p	/2024 /2024 tive \$	Secu calls	s, Wa 5. Na 5. Na	es Acquarrants umber vative urities uired	8) Code M S uired, I , optio	V Disp ns, (16,500 16,500 posed of, convertil sable and	(D) A D or Bene	\$8.69 \$28.73 eficially rities) d Amount es Security	Owned I Reporte Transac (Instr. 3 16	Following d tion(s) and 4) ,500	r of s lly	D	Beneficial Dwnership	
Commo	e 2. Conversion or Exercise Price of Derivative	3. Transaction Date	3A. Deem Execution if any	11/18/ 11/18/ • Deriva (e.g., p ed Date, sy/Year)	/2024 /2024 tive \$ puts, 4. Transaa Code (I	Secu calls	s, Wa 5. Na 5. Na	es Acquarrants umber vative urities uired or oosed o) (Instr.	8) Code M S uired, I , optio	V Disp ns, (16,500 16,500 posed of, convertil sable and	(D) A D Or Bene ble secu	\$8.69 \$28.73 eficially rities) d Amount es Security	Owned I Reporte Transac (Instr. 3 16 0 8. Price of Derivative Security	Following d tion(s) and 4) ,500 0 9. Numbe derivative Beneficia Owned Following Reported Transacti	r of s lly	D II. Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership	

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of \$28.47 to \$29.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

2. The option was granted on March 2, 2022. The shares underlying the option are scheduled to vest over three years in equal monthly installments through March 2, 2025.

<u>/s/ Richard Scalzo, Attorney</u>	<u>/-in-</u>	11/18/2024
Fact		11/16/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.